News ASH: Regeneron makes frontline case for Lynozyfic in myeloma Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma.
News ASH: AstraZeneca's dual-wielding CAR-T shows promise AstraZeneca has reported an impressive 96% response rate in the DURGA-1 of BCMAxCD19 CAR-T therapy AZD0120 in heavily pretreated multiple myeloma.
News Protego's $130m for amyloidosis drug, and other financings Our latest crop of biotech financings has nine-figure rounds for Protego and Triana, with Excelsior Sciences and SciNeuro also raising new funds.
News BMS's Breyanzi is first CAR-T for marginal zone lymphoma Bristol Myers Squibb has taken CAR-T therapy into new territory, after getting FDA approval for Breyanzi in marginal zone lymphoma.
News Setback for MSD as German court blocks Keytruda SC launch A court in Germany has granted an injunction that will prevent MSD from distributing the new, subcutaneous version of its cancer drug Keytruda.
News Lilly gets approval for earlier use of Jaypirca in CLL Eli Lilly's fast-growing Jaypirca has won a new FDA approval as an earlier treatment for relapsed/refractory chronic lymphocytic leukaemia.
News Philanthropic drive puts $140m behind strep A vaccine A $140m fund launched by philanthropic group Coefficient Giving will try to find the first vaccine for Strep A, which kills 639,000 people a year.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.